Lipids, blood pressure and bone metabolism after growth hormone therapy in elderly hemodialysis patients

Journal of Nephrology

Volumn 16, Issue 2, 2003, Pages 231-237

  Viidas, Unni ^a   Johannsson, Gudmundur ^b   Mattson Hultén, Lena ^b   Ahlmén, Jarl ^a  

^a SKARABORG HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Blood pressure; Elderly patients; Growth hormone; Hemodialysis; Lipids

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; COLLAGEN TYPE 1; HIGH DENSITY LIPOPROTEIN; HUMAN GROWTH HORMONE; LIPOPROTEIN; OSTEOCALCIN; PLACEBO; PROCOLLAGEN; TRIACYLGLYCEROL;

AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BONE METABOLISM; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; ELDERLY CARE; GERIATRIC PATIENT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HORMONAL THERAPY; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; LIPID METABOLISM; NORMAL VALUE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; UREMIA; AGE; BLOOD PRESSURE MEASUREMENT; BONE DENSITY; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PROBABILITY; REFERENCE VALUE; RENAL REPLACEMENT THERAPY; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; BONE DENSITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMAN GROWTH HORMONE; HUMANS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; LIPID METABOLISM; MALE; MIDDLE AGED; PROBABILITY; REFERENCE VALUES; RENAL DIALYSIS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0042521126     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Schön S, 1999 [Swedish Registry for Active Treatment of Uremia] Department of Nephrology, Skaraborgs Hospital.
2. Moss AH. Dialysis decisions and the elderly. Clin Geriatr Med 1994; 10: 463-73.
3. United States Renal Data System. USRDS 1998 Annual Report. National Institutes of Health. National Institutes of Diabetes and Kidney Diseases, Bethesda, MD, 1998.
4. Blagg C. Importance of nutrition in dialysis patients. Am J Kidney Dis 1991; 17: 458-61.
5. Tönshoff B, Mehls O, Heinrich U, Blum WF, Ranke MB, Schauer A. Growth-stimulating effects of recombinant human growth hormone in children with end-stage renal disease. J Pediatr 1990; 116: 561-6.
6. Johansson G, Bengtsson B-Å, Ahlmén J. Double blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: Anabolic effect and functional improvement. Am J Kidney Dis 1999; 33: 709-17.
7. Angelin B, Rudling M. Growth hormone and hepatic lipoprotein metabolism. Curr Opin Lipidol 1994; 5: 160-5.
8. Friedewald WT, Levy RL, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
9. Edén S, Wiklund O, Oscarsson J, Rosén T, Bengtsson B-Å. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb Vasc Biol 1993; 13: 296-301.
10. Petterson A, Uggla L, Backman V. Determination of dimethylated arginines in plasma by high performance liquid chromatography. J Chromatogr 1997; 692: 257-62.
11. Viidas U, Ahlmén J, Hedner T, Cajdahl K, Larsson A, Petterson A, Strömbom U. Nitric oxide in bloodpressure in normotensive patients on chronic hemodialysis. Dial Transplant 1998; 27: 714-23.
12. Matthews JN, Altman DC, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990; 300: 230-5.
13. Bengtsson B-Å, Edén S, Lönn L, Kvist H, Stokland A, Lindstedt G, Bosaeus I, Tölli J, Sjöström L, Isaksson OGP. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993; 76: 309-17.
14. Møller J, Frandsen E, Fisker S, Jørgensen JO, Christiansen JD. Decreased plasma and extracellular volume in growth-hormone deficient adults and the acute and prolonged effects of GH administration - A controlled experimental study. Clin Endocrinol 1996; 44: 533-9.
15. Amato G, Carella C, Fazio S, La Montagna G, Cittadini A, Sabatini D, Marciano-Mone C, Saccá L, Bellastella A. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 1993; 77: 1671-6.
16. Beshyah SA, Shahi M, Skinner E, Sharp P, Foale R, Johnston DG. Cardiovascular effects of growth hormone replacement therapy in hypopituitary adults. Eur J Endocrinol 1994; 130: 451-8.
17. Cittadini A, Cuocolo A, Merola B, Fazio S, Sabatini D, Nicolai E, Colao A, Longobardi S, Lombardi G, Saccá L. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement. Am J Physiol 1994; 267: E219-25.
18. Fort S, Weaver JU, Monson JP, Mills PG. The effects of low-dose recombinant human growth hormone on cardiovascular structure and function in hypopituitary growth hormone-deficient adults. Endocrinol Metab 1995; 2: 119-26.
19. Valcavi R, Gaddi O, Zini M, Lavicoli M, Mellino U, Portioli I. Cardiac performance and mass in adults with hypopituitarism: Effects of one year of growth hormone treatment. J Clin Endocrinol Metab 1995; 80: 659-66.
20. Böger RH, Skamira C, Bode-Böger SM, Brabant G, Von Zur Mühlen A, Frölich JC. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. J Clin Invest 1996; 98: 2706-13.
21. Caidahl K, Edén S, Bengtsson B-Å. Cardiovascular and renal effects of growth hormone. Clin Endocrinol 1994; 40: 393-400.
22. Johansson G, Rosén T, Lindstedt G, Bosaeus I, Bengtsson B-Å. Effects of 2 years of growth hormone treatment on body composition and cardiovascular risk factors in adults with growth hormone deficiency. Endocrinol Metab 1996; 3 (suppl A): S3-12.
23. Marcus R, Butterfield G, Holloway L. Effects of short term administration of recombinant human growth hormone to elderly people. J Clin Endocrinol Metab 1990; 70: 519-27.
24. Johannsson G, Rosén T, Bosaeus I, Sjöström L, Bengtsson B-Å. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult onset GH-deficiency. J Clin Endocrinol Metab 1996; 81: 2865-73.
25. Fuh MM, Lee C-M, Jeng C-Y, Shen D-C, Shieh S-M, Reaven GM, Chen Y-DI. Effect of chronic renal failure on high-density lipoprotein kinetics. Kidney Int 1990; 37: 1295-300.
26. Johansson G, Oscarsson J, Rosén T, Wilkund O, Olsson G, Wilhelmsen L, Bengtsson B-Å. Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults: Influence of gender and apo (a) and apoE phenotypes. Arterioscler Thromb Vasc Biol 1995; 15: 2142-50.
27. Johansson G. Effects of GH on lipid metabolism. In Bengtsson B-Å Ed. Growth Hormone. AH Dordrecht: Kluwer Academic Publishers 1999; 149-63.
28. Sjöberg A, Oscarsson J, Edén S, Olofsson S-O. Continuous but not intermittent administration of growth hormone to hypophysectomized rats increases apolipoprotein-E secretion from cultured hepatocytes. Endocrinology 1994; 134: 790-8.
29. Johannson G, Mårin P, Lönn L, Ottosson M, Stenlöf K, Björntorp P, Sjöström L, Bengtsson B-Å. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 1997; 82: 727-34.
30. Björntorp B. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10: 493-6.
31. Ottoson M, Vikman-Adolfsson K, Enerbäck S, Elander A, Björntorp P, Edén S. Growth hormone inhibits lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab 1995; 80: 936-41.
32. Oscarsson J, Ottosson M, Johansson J-O, Wiklund O, Mårin P, Bengtsson B-Å. Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults: II Effects on serum lipoproteins and lipoprotein and hepatic activity. Metabolism 1996; 370-7.
33. Oscarsson J, Ottosson M, Vikman-Adolfsson K, Frick F, Enerbäck S, Lithell H, Edén S. GH but not IGF-I or insulin increases lipoprotein lipase activity in muscle tissues of hypophysectomised rats. J Endocrinol 1999; 160: 247-55.
34. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: A prospective case control study in a general population sample of middle aged men. Br Med J 1990; 301: 1248-51.